OBJECTIVES: Multiple sclerosis (MS) is a chronic inflammatory disease with 12,000 new diagnoses per year in the United States. Higher latitude is associated with higher MS prevalence rates, and the female-to-male ratio in MS incidence has been estimated at 2:3 in 2000. This study aims to estimate the prevalence and incidence rate of MS in the United States. METHODS: Patients with an MS diagnosis (International Classification of Diseases Ninth Revision Clinical Modification [ICD-9-CM] code: 340.XX) between January 2006 and December 2010 were identified from a large U.S. claims database. Prevalence rates from 2006 to 2010 were calculated by dividing the number of MS patients by the total number of health plan enrollees in each year. The 2010 incidence rate was calculated by dividing the number of patients with a new MS diagnosis in 2010 by the total number of enrollees in 2010.
OBJECTIVES:
One important aspect for patients suffering from multiple sclerosis (MS) is the frequency and severity of relapses that lead to a significant increase in symptoms and an aggravation of health related quality of life. In this study, data of about 3,000 MS patients have been analysed over a five year period in order to identify the number of relapses and the events that may follow a relapse. METHODS: Information was taken from 2006 to 2010 German claims data. To identify a relapse, several indicators such as hospitalisations, specific relapse medication and outpatient consultations have been investigated. RESULTS: The results show that the identification of relapses can be achieved by including inpatient, outpatient and relapse medication data. Relapses were found for 47% of all MS patients. Among those receiving MS medication, 67% suffered from relapses while only 32% of the patients without medication were affected. This may indicate that the proportion of patients having a higher risk of relapses is usually under MStreatment. Most patients with relapses (64%) did not show more than three relapses within five years. The events following a relapse were classified by the number of hospitalisations (14% within one month after the relapse), transitions from basic to escalating MS medication (3% within one quarter after the relapse) or changes of disease modifying drug (3% within one quarter after the relapse). Changes of basic MS medication are not necessarily related to relapses, while changes from basic to escalating MS medication are often observed after such an event. CONCLUSIONS: Patients with high frequencies of relapses are treated with disease modifying drugs more often than other patients. Most of the MS patients do not suffer from relapses within the observation period of five years, with a small group of patients suffering from numerous relapses.
PND10 FASTER COGNITIVE DECLINE IS ASSOCIATED WITH DECREASING SURVIVAL IN PATIENTS WITH ALZHEIMER'S DISEASE
van Sanden S 1 , Diels J 2 , Gaudig M 3 , Spencer M 4 , Thompson G 5 , Arrighi HM 6 1 EMEA HEMAR Analytics, Janssen EMEA, Beerse, Belgium, 2 Janssen Pharmaceutica, Beerse, Belgium, 3 Janssen Alzheimer Immunotherapy, Dublin, Ireland, High Wycombe, Bucks, UK, High Wycombe, UK, 6 Janssen Alzheimer Immunotherapy, San Francisco, CA, USA OBJECTIVES: To explore the impact of severity and rate of decline of cognitive impairment on mortality within Alzheimer's disease (AD) patients. METHODS: Data on AD patients were from CERAD (Consortium to Establish a Registry for Alzheimer's Disease), a US multicenter, longitudinal study. Patient demographics, cardiovascular and other co-morbidities, activities of daily living (ADL), cognitive impairment measured by the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating (CDR), and survival status were obtained at study entry (baseline), and at annual follow-up visits. Study survival time was modelled as a function of patient baseline demographics, cognitive impairment at entry and its decline over time using parametric survival models and semi-parametric Cox proportional hazard model (PH), with decline of cognitive impairment as a time-dependent covariate. RESULTS: 1010 patients with non-missing survival data were included in the analysis. At baseline, men, age and cognitive impairment significantly increased the mortality risk (pϽ0.001 for all). Additionally, patients progressing to a more severe stage of cognition over time had significantly higher mortality risk (pϽ0.001), with a hazard ratio for CDR change over time versus baseline as a time dependent covariate of 1.35 [95% CI: 1.21-1.51]. CDR and MMSE scores were highly correlated; results based on models using either CDR or MMSE were mostly consistent. Results were confirmed by sensitivity analyses with varying modelling assumptions. CONCLUSIONS: Severity and rate of decline of cognitive impairment are both strong predictors of survival in AD, additional to the usual demographic and clinical patient characteristics. These findings suggest that treatments delaying the progression of AD patients to more severe stages of cognitive impairment might positively impact overall survival.
PND11 ESTIMATING SURVIVAL-BENEFIT OF NEW THERAPEUTIC INTERVENTIONS IN CYSTIC FIBROSIS PATIENTS IN GERMANY, FRANCE, UK AND IRELAND
Becker CC, Kim M, Johnson C Vertex Pharmaceuticals, Cambridge, MA, USA OBJECTIVES: Cystic fibrosis (CF), the most common lethal genetic disease in Caucasians, causes a high burden of disease. Median age at death is in the late 20s with the most common mode of death being respiratory failure. Treatment with ivacaftor, a CF transmembrane conductance regulator (CFTR) protein potentiator, was generally safe and improved risk-factors for mortality in CF, including pulmonary function, weight and pulmonary exacerbations. Since controlled clinical trials cannot directly demonstrate survival benefits, we estimated the potential for survival benefit from drug therapies based on similar, observed short-term changes to risk factors known to impact survival in CF. METHODS: Survival information for CF patients in Germany, France, the UK, and Ireland was obtained from national registries and individually fitted to a Weibull function. From these survival curves the hazard function for an average CF patient was calculated as a function of age. The impact to the hazard function from improvements in risk factors (FEV1, weightfor-age z-score, pancreatic sufficiency, diabetes, Staphylococcus aureus, Burkholderia cepacia, and annual number of pulmonary exacerbations) was estimated using previously published Cox proportional hazards model for CF mortality. RESULTS: For each country, a survival function was developed taking into account current average mortality rates and estimated long-term changes to risk factors. Sensitivity analysis suggest that it is possible for drugs that improve clinical outcomes in CF, including pulmonary function, weight and pulmonary exacerbations, to add a decade to the median life expectancy CF patients. CONCLUSIONS: Modeling suggests that therapies that improve clinical risk factors for mortality in CF, including pulmonary function, weight and pulmonary exacerbations, may extend the lives of CF patients.
NEUROLOGICAL DISORDERS -Cost Studies

PND12 BUDGET IMPACT ANALYSIS OF ROUTINE TESTING FOR GENETICALLY BASED CARDIOPATHIES ASSOCIATED WITH HIGH RISK OF SUDDEN DEATH IN SPAIN: PRELIMINARY RESULTS
Fernández I 1 , García-Pavía P 1 , Ripoll T 2 , Boldeanu A 3 , Gracia A 4 , Ramírez de Arellano A 4 , Aceituno S 5 , Lizán L 5 , Puig-Gilberte J 6 , Salas E 6 1 Hospital Universitario Puerta del Hierro, Madrid, Spain, 2 Hospital Son Llàtzer, Palma de Mallorca, Spain, 3 FERRER-inCode, Barcelona, Spain, 4 Ferrer Grupo, Barcelona, Spain, 5 Outcomes 10, Castellón, Spain, 6 GENDIAG, Barcelona, Spain OBJECTIVES: To estimate the economic impact of introducing the test for diagnosing the five cardiopathies associated to SCD related to the currently best known genes in Spain: 1.Hypertrophic Cardiomyopathy (HCM); 2.Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC); 3.Long-QT Syndrome (LQTS); 4.Brugada Syndrome (BrS), and 5.Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). METHODS: A 3-year budget impact analysis was carried out based on international sources of epidemiological and health care resource utilization data; local input costs and market share, and expert opinion. Two scenarios were compared: current clinical practice (with no genetic testing) vs. alternative practice (with genetic testing). The perspective adopted was that of the Spanish National Healthcare System (NHS). All costs referred to €, 2012. RESULTS: The target population at risk of SCD was estimated on 25,220 patients for year 1; 26,352 for year 2, and 26,340 for year 3. Genetic testing would be conducted in 350, 550 and 700 patients in 2012, 2013 and 2014, respectively. The budget impact of introducing the genetic testing would imply an additional cost of € 309,187, € 532,311, and € 724,404, respectively. Genetic testing compared to current practice would imply cost savings of € 10,152 and of € 41,062, in the first year; of € 30,327 and € 84,026, in the second, and of € 57,269 and € 126,660 in the third year derived from two reasons: preventing new events in patients at risk and from averting follow-up in patients at no risk, respectively. CONCLUSIONS: Potential cost savings derived from preventing new events and unnecessary follow-up may overcome the costs of introducing the genetic testing for HCM, ARVC, LQTS, BrS and CPVT in the Spanish NHS.
PND13 BUDGET IMPACT ANALYSIS AND UPDATE OF A COST EFFECTIVENESS EVALUATION FOR ALPHA (␣) POLYMORPH RIFAXIMIN FOR THE TREATMENT OF ACUTE HEPATIC ENCEPHALOPATHY
time horizon and resources usage from a previous cost-effectiveness study for medications used to treat hepatic encephalopathy from the Mexican Institute of Social Security (IMSS) perspective and to complement it with a budget impact analysis. METHODS: CE analysis of treatments used for acute HE, based in a decision tree model, and considering a horizon of 10 days. Alternatives available at the IMSS are: lactulose, L-ornithine L-aspartate (LOLA), neomycin and alpha (a)polymorph rifaximin (the new alternative). Percentage of patients with improvement in signs and symptoms of HE was the effectiveness measure and s based on available published studies (Huang 2007 and Qian 2009) . Only direct medical costs were considered and obtained from IMSS. Univariated sensitivity analysis, using pricing discounts and effectiveness were performed and budget impact simulations were developed. RESULTS: LOLA US$4024, lactulose US$4032, neomycin US$4060 and rifaximin US $4039 final costs. In relation to effectiveness, the percentage of patients who presented improved signs and symptoms for each alternative is as follows: lactulose and LOLA 55%, neomycin 64% and rifixamin 90%. Cost effectiveness ratios are: lactulose US$7331, LOLA $7316, neomycin US$6344 and rifixamin US$4488. The incremental cost effectiveness analysis indicates that LOLA and neomycin are surpassed by lactulose and rifaximin, which are located on the efficiency line. For the sensitivity analysis with one hospitalization day reduced due to the improved efficacy, rifaximin was the dominating alternative. If lactulose and neomycin are substituted by rifaximin in the estimated population(6,194 to 21,680 potential range of patients with HE in the Mexican Health System), the budget impact shows savings equivalent to 77.74 y 72.36%, respectively. CONCLUSIONS: Alpha (a) polymorph rifaximin is a highly cost effective alternative for treating acute HE from an institutional perspective in México.
PND14 BUDGETARY IMPACT OF THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN
García-Ruiz AJ 1 , Izquierdo Ayuso G 2 , Garcia-Agua Soler N 3 1 Malaga University, Malaga, Spain, 2 Universitary Hospital, Seville, Spain, 3 University of Malaga, Malaga, Spain OBJECTIVES: To estimate the budgetary impact of RRMS treatment from the perspective of the NHS in Spain (valued Euros-2011), in order to determine which treatment is most efficient from the payer's perspective. METHODS: IMS sales data for multiple sclerosis drugs were used to estimate the total number of patients treated with each of the drugs used during 2011. The number of patients receiving treatment was calculated from the yearly cost of each treatment per patient (exfactory price excluding VAT) because IMS presents total sales expressed as exfactory price, which means that the yearly cost of the drug expressed as ex-factory price must be used to estimate the number of patients from the IMS sales data. Although there are clear differences in the effectiveness of the treatments used, these differences do not always explain differences in prices (higher incremental costs). RESULTS: Total expenditure in Spain in 2011 was €259 million. Among the patients, 47% were treated with interferon beta-1a, 27% with interferon beta-1b, 16% with glatiramer acetate and 10% with natalizumab. In the unlikely event that all patients had used interferon beta-1a in Spain, total expenditure would have been between -10% and ϩ6.3%, depending on the drug used. If interferon beta 1b had been used by all patients, the total savings in Spain during 2011 would have been over 12.5%. Nonetheless, the greatest savings (Ͼ15% of total expenditure) would have been achieved if all patients had been treated with glatiramer acetate. CONCLUSIONS: Despite the limitations of the study (only direct drug costs were considered and the number of patients receiving treatment was extrapolated) this methodology may aid decision-making by policy makers, especially in times of economic difficulty, by showing which medication is more efficient.
PND15
COST-EFFECTIVENESS OF BUCCOLAM® (LICENSED OROMUCOSAL MIDAZOLAM) COMPARED TO BENZODIAZEPINES FOR THE TREATMENT OF ACUTE PROLONGED EPILEPTIC SEIZURES IN GERMANY
Lee D, Gladwell D, Batty A, Brereton NJ BresMed, Sheffield, UK OBJECTIVES: BUCCOLAM (oromucosal midazolam) is approved for the treatment of prolonged, acute, convulsive seizures in children and was the first product to receive a Paediatric-Use Marketing Authorisation (PUMA) in September 2011. The product label includes use by parents and other carers such as teachers. Current care in Germany for first line treatment consists mainly of rectal diazepam with some use of buccal lorazepam, clonazepam and chloral hydrate. Some non-family carers can be reluctant to administer these products due to concerns about social acceptability, dignity or labelling issues. A decision tree model has been developed to assess the cost of BUCCOLAM compared to current care for prolonged acute convulsive seizures initially occurring in the community setting. METHODS: The model evaluates costs along the treatment pathway when a child has a seizure including whether or not carers administer treatment, whether an ambulance is required and whether or not patients are taken to hospital and require an inpatient stay. Data were obtained from a variety of sources including clinical effectiveness estimates from McIntyre et al. 2005 , and a Delphi panel. Costs were taken from published sources. Estimates of the total eligible population were taken from epilepsy prevalence data and the Delphi panel. RESULTS: Over one year, compared to the mix of treatments representing current care, BUCCOLAM showed a reduction in per patient costs of €3,469. Compared to treatment with rectal diazepam alone, the most commonly used treatment, BUCCOLAM showed a cost reduction of €3,533. It was expected that ϳ36,000 patients would be eligible. At an uptake of 20% BUCCOLAM would reduce health care expenditure by €19.4 million in the first year. CONCLUSIONS: Treatment with BUCCOLAM is cost-saving compared to current care and treatment with rectal diazepam through a reduction in the need for ambulance call-outs and hospital stays.
PND16
COST-EFFECTIVENESS ANALYSIS OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN ADULTS WITH PARTIAL-ONSET SEIZURES IN MEXICO
Aguirre A 1 , Sentíes H 2 , Córdova S 3 , Benitez A 1 1 UCB de México, Mexico City, D.F., Mexico, 2 Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, DF, Mexico, 3 Hospital Español de México, Mexico City, DF, Mexico OBJECTIVES: Epilepsy is one of the most common chronic neurological disorders in the world; therefore it is associated with substantial use of medical resources in health institutions. Approximately 60% of patients with epilepsy suffer from partial-onset seizures (POS), and among these, an estimated 30% have refractory disease. The objective of this study was to analyze the cost-effectiveness of lacosamide (LCM), a newer anti-epileptic drug (AED), versus second generation AEDs in patients with refractory POS. METHODS: We conducted an economic evaluation, using lamotrigine (LTG) 300 mg/day and topiramate (TPM) 200 mg/day as comparators for LCM 200 and 400 mg/day. The perspective was the Mexican Social Security Institute, in accordance with Mexican guidelines for Economic Evaluations. The model included the cost of drug acquisition and management of adverse events (AE) during the titration and 12 weeks of maintenance. Resource use associated with AEs was defined according to the information gathered in a Delphi Panel. The efficacy measure was the Ն50% responder rate; i.e., the percentage of patients who showed a Ն50% decrease in seizure frequency from baseline. An indirect comparison was made. RESULTS: The adjusted response rates were 33% for LCM 200 mg/day (34% unadjusted), 39% LCM 400 mg/day (41% unadjusted), 24% for LTG (20% unadjusted) and 31% for TPM (27% unadjusted). Costs per patient considering the adjustment was MX$6, 872, $7, 836, $6, 954 and $6, 485 for LCM 200 mg, LCM 400 mg, LTG and TPM, respectively. The cost per responder was lower for LCM 200 and 400 mg/day ($20, 825 and $20, 093, respectively) than TPM and LTG ($20, 918 and $28, 974, respectively) . Considering unadjusted data, LCM 200 and 400 mg/day had greater differential in costs per responder compared with TPM or LTG. CONCLUSIONS: From a Mexican perspective, lacosamide represents a cost-effective treatment option for patients with POS. Sponsored by UCB.
PND17 COMPARING COST OF THERAPEUTIC PLASMA EXCHANGE AND INTRAVENOUS IMMUNOGLOBULIN INFUSION IN TREATING GUILLAIN-BARRÉ SYNDROME
Atikeler K 1 , Tuna E 2 , Kockaya G 3 1 Ankara University, Ankara, Turkey, 2 Hacettepe University, Ankara, Turkey, 3 Health Economics and Policy Association, Ankara, Turkey OBJECTIVES: Controlled trials have found therapeutic plasma exchange (TPE) and intravenous immunoglobulin (IVIg) infusion therapy to be equally efficacious in treating Guillain-Barré syndrome (GBS). Due to increases in the price of IVIg compared to human serum albumin (HSA), used as a replacement fluid in TPE, direct hospital-level expenditures for TPE and IVIg for meaningful cost-differences between these treatments were exemined for Turkey. METHODS: Cost were calculated with Hacettepe University Hospital procedures for one cycle IVIg and TPE. One cycle were defined for IVIg and TPE as 5 days and 5 series, respectively. A model was developed which allows hospitals to input cost and reimbursement amounts for both IVIg and TPE with HSA that results in real-time valuations of these interventions. Reimbursement amounts were obtained from publicly available Social Security Institution (SGK) data resources to determine payment rates for TPE and IVIg. Only direct cost and payer perspective were used for the calculation. RESULTS: The direct cost of IVIg infusion sessions totaling 140,0 grams for 5 days was 18,841 TL compared to a series of five TPE procedures, which had direct costs of 6,529 TL. CONCLUSIONS: In GBS patients, direct costs of IVIg therapy are more than twice that of TPE. Given equivalent efficacy and similar severity and frequencies of adverse events, TPE appears to be a less expensive first-line therapy option for treatment of patients with GBS for Turkey.
PND18
IMPACT OF CO-MORBIDITIES ON THE ECONOMIC BURDEN OF PARKINSON'S DISEASE IN GERMANY POST-2000
Takyar S, Kataria A, Rajput A, Kaur M Heron Health Pvt. Ltd., Chandigarh, India OBJECTIVES: To collate the published evidence evaluating economic burden of co-morbidities in patients with Parkinson's disease (PD) in Germany. METHODS: A systematic search of electronic literature databases (Embase ® and MEDLINE ® ) was conducted from January 2001 to June 2012 to identify economic studies in English evaluating co-morbidities in patients with PD in Germany. RESULTS: Four studies of the 267 citations retrieved met the pre-defined inclusion criteria. During 2000-2002, direct costs were higher in patients with dyskinesias and/or motor fluctuations (€3300 [€4630]) or dementia (€3110 [€5610]) than patients without motor complications (€1450 [€3760]) or dementia (€1530 [3460]). However, indirect costs were higher for patients without dementia (€3780 [€6870]) than patients with dementia (€1080 [€4110]). In 2006, daily total costs and PD drug treatment costs decreased significantly in patients with dementia (€7.3 [7.3]; pϽ0.05) and depression (€6.6 [5.8]; pϽ0.05) than patients without dementia (€9.3 [13.9]) and depression (€7.6 [6.8]), respectively. The decrease in the costs observed across patients presenting with these co-morbidities may be attributed to the inadequate treatment of depression or dementia among patients with PD. In 2009, direct costs demonstrated a significant increase in patients with dyskinesia (€16,544 vs. €11,322; pϭ0.003), dementia (€21,142 vs. €10,619; pϽ0.001), depression (€15,904 vs. €8826; pϽ0.001), or psychosis A548
